Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 38

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 38
---
 to complete and may not be completed in a timely manner, or at all, due to pending or potential litigation or regulatory challenges.

The proposed Merger and related transactions
may be challenged in court by shareholders or other interested parties. While management believes any such claims would be without merit,
we may be subject to various lawsuits or other legal proceedings, including but not limited to shareholder class action lawsuits alleging
breaches of fiduciary duties related to the proposed transaction structure, valuation, conflicts of interest (including those set forth
in this proxy statement in the section titled “Interests of the TELO Directors, Executive Officers and Affiliate Shareholders in the Merger”on page 34)or disclosure. Responding to and defending against these claims can be time-consuming, expensive,
and could divert management’s attention and resources away from day-to-day business operations.

Further, government agencies, including
antitrust authorities, may seek to block, delay, or impose conditions on the Merger. These regulatory reviews and filings are a common
aspect of mergers and acquisitions and are subject to significant costs, including substantial legal fees and potential judgments or
settlements; transaction delays or the inability to close the merger on the contemplated terms; the imposition of burdensome conditions
or restrictions on the combined company’s operations; or the termination of the Merger agreement altogether, which could have a material
adverse effect on our business, financial condition, and stock price

There has been no public market for TELI Common Stock and the lack of a public market may make it more difficult to determine the fair market value of TELI than if there were such a public market.

The outstanding shares of TELI Common Stock are privately held and are not traded on any public market. The lack of a public market makes it more difficult to determine the fair market value of TELI than if the outstanding shares of TELI Common Stock were traded publicly. The value ascribed to TELI in the Merger and in the Merger Consideration may not be indicative of the price at which the outstanding shares of TELI Common Stock may have traded on a public market if such were available. The Merger Consideration to be paid to TELI stockholders was determined based on negotiations between TELI and TELI and not on the basis of market prices. The relative values of TELI and TELI may not be indicative of the price at which the shares of TELI Common Stock may have been traded on a public